BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Major ME, Mihalik K, Puig M, Rehermann B, Nascimbeni M, Rice CM, Feinstone SM. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol. 2002;76:6586-6595. [PMID: 12050371 DOI: 10.1128/jvi.76.13.6586-6595.2002] [Cited by in Crossref: 146] [Cited by in F6Publishing: 58] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Capone S, Meola A, Ercole BB, Vitelli A, Pezzanera M, Ruggeri L, Davies ME, Tafi R, Santini C, Luzzago A, Fu TM, Bett A, Colloca S, Cortese R, Nicosia A, Folgori A. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J Virol 2006;80:1688-99. [PMID: 16439526 DOI: 10.1128/JVI.80.4.1688-1699.2006] [Cited by in Crossref: 64] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
2 Kakimi K. Immune-based novel therapies for chronic hepatitis C virus infection. Hum Cell 2003;16:191-7. [PMID: 15147039 DOI: 10.1111/j.1749-0774.2003.tb00153.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
3 Cashman SB, Marsden BD, Dustin LB. The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol. 2014;5:550. [PMID: 25426115 DOI: 10.3389/fimmu.2014.00550] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
4 Major ME. Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives. Viruses 2009;1:144-65. [PMID: 21994543 DOI: 10.3390/v1020144] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
5 Rehermann B, Thimme R. Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection. Gastroenterology 2019;156:369-83. [PMID: 30267712 DOI: 10.1053/j.gastro.2018.08.061] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 12.5] [Reference Citation Analysis]
6 Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005;11:791-796. [PMID: 15951748 DOI: 10.1038/nm1268.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Dustin LB. Innate and Adaptive Immune Responses in Chronic HCV Infection. Curr Drug Targets 2017;18:826-43. [PMID: 26302811 DOI: 10.2174/1389450116666150825110532] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
8 Berzofsky JA, Ahlers JD, Janik J, Morris J, Oh S, Terabe M, Belyakov IM. Progress on new vaccine strategies against chronic viral infections. J Clin Invest. 2004;114:450-462. [PMID: 15314679 DOI: 10.1172/jci200422674] [Cited by in Crossref: 90] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
9 Goyal A, Lurie Y, Meissner EG, Major M, Sansone N, Uprichard SL, Cotler SJ, Dahari H. Modeling HCV cure after an ultra-short duration of therapy with direct acting agents. Antiviral Res 2017;144:281-5. [PMID: 28673800 DOI: 10.1016/j.antiviral.2017.06.019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
10 Nascimbeni M, Mizukoshi E, Bosmann M, Major ME, Mihalik K, Rice CM, Feinstone SM, Rehermann B. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol. 2003;77:4781-4793. [PMID: 12663785 DOI: 10.1128/jvi.77.8.4781-4793.2003] [Cited by in Crossref: 144] [Cited by in F6Publishing: 71] [Article Influence: 7.6] [Reference Citation Analysis]
11 Kaplan DE. Immunopathogenesis of Hepatitis C Virus Infection. Gastroenterol Clin North Am 2015;44:735-60. [PMID: 26600217 DOI: 10.1016/j.gtc.2015.07.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
12 Manigold T, Shin EC, Mizukoshi E, Mihalik K, Murthy KK, Rice CM, Piccirillo CA, Rehermann B. Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. Blood. 2006;107:4424-4432. [PMID: 16478885 DOI: 10.1182/blood-2005-09-3903] [Cited by in Crossref: 91] [Cited by in F6Publishing: 78] [Article Influence: 5.7] [Reference Citation Analysis]
13 Lee H, Jeong M, Oh J, Cho Y, Shen X, Stone J, Yan J, Rothkopf Z, Khan AS, Cho BM, Park YK, Weiner DB, Son WC, Maslow JN. Preclinical evaluation of multi antigenic HCV DNA vaccine for the prevention of Hepatitis C virus infection. Sci Rep 2017;7:43531. [PMID: 28266565 DOI: 10.1038/srep43531] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
14 Cox AL, Thomas DL. Hepatitis C virus vaccines among people who inject drugs. Clin Infect Dis. 2013;57 Suppl 2:S46-S50. [PMID: 23884065 DOI: 10.1093/cid/cit329] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
15 Tarr AW, Urbanowicz RA, Ball JK. The role of humoral innate immunity in hepatitis C virus infection. Viruses. 2012;4:1-27. [PMID: 22355450 DOI: 10.3390/v4010001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
16 Kato T, Choi Y, Elmowalid G, Sapp RK, Barth H, Furusaka A, Mishiro S, Wakita T, Krawczynski K, Liang TJ. Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation. Hepatology. 2008;48:732-740. [PMID: 18712792 DOI: 10.1002/hep.22422] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 3.4] [Reference Citation Analysis]
17 Kato T, Matsumura T, Heller T, Saito S, Sapp RK, Murthy K, Wakita T, Liang TJ. Production of infectious hepatitis C virus of various genotypes in cell cultures. J Virol 2007;81:4405-11. [PMID: 17301131 DOI: 10.1128/JVI.02334-06] [Cited by in Crossref: 86] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis]
18 Sepulveda-Crespo D, Resino S, Martinez I. Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants. Vaccines (Basel) 2020;8:E313. [PMID: 32560440 DOI: 10.3390/vaccines8020313] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
19 Grubor-Bauk B, Yu W, Wijesundara D, Gummow J, Garrod T, Brennan AJ, Voskoboinik I, Gowans EJ. Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell-mediated immunity in mice and pigs. Gene Ther 2016;23:26-37. [PMID: 26262584 DOI: 10.1038/gt.2015.86] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
20 Honegger JR, Zhou Y, Walker CM. Will there be a vaccine to prevent HCV infection? Semin Liver Dis. 2014;34:79-88. [PMID: 24782261 DOI: 10.1055/s-0034-1371081] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
21 Hartlage AS, Kapoor A. Hepatitis C Virus Vaccine Research: Time to Put Up or Shut Up. Viruses 2021;13:1596. [PMID: 34452460 DOI: 10.3390/v13081596] [Reference Citation Analysis]
22 Chen Z, Zhu Y, Ren Y, Tong Y, Hua X, Zhu F, Huang L, Liu Y, Luo Y, Lu W. Hepatitis C virus protects human B lymphocytes from Fas-mediated apoptosis via E2-CD81 engagement. PLoS One. 2011;6:e18933. [PMID: 21526201 DOI: 10.1371/journal.pone.0018933] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
23 Tesfaye A, Stift J, Maric D, Cui Q, Dienes HP, Feinstone SM. Chimeric mouse model for the infection of hepatitis B and C viruses. PLoS One 2013;8:e77298. [PMID: 24155939 DOI: 10.1371/journal.pone.0077298] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.2] [Reference Citation Analysis]
24 Grebely J, Pham ST, Matthews GV, Petoumenos K, Bull RA, Yeung B, Rawlinson W, Kaldor J, Lloyd A, Hellard M. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology. 2012;55:1058-1069. [PMID: 22031335 DOI: 10.1002/hep.24754] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 6.7] [Reference Citation Analysis]
25 Sung PS, Racanelli V, Shin EC. CD8(+) T-Cell Responses in Acute Hepatitis C Virus Infection. Front Immunol 2014;5:266. [PMID: 24936203 DOI: 10.3389/fimmu.2014.00266] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
26 Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, Feinstone SM, Alter H, Rice CM, McKeating JA. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci USA. 2004;101:10149-10154. [PMID: 15220475 DOI: 10.1073/pnas.0403519101] [Cited by in Crossref: 303] [Cited by in F6Publishing: 298] [Article Influence: 16.8] [Reference Citation Analysis]
27 Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005;11:791-796. [PMID: 15951748 DOI: 10.1038/nm1268] [Cited by in Crossref: 2145] [Cited by in F6Publishing: 2068] [Article Influence: 126.2] [Reference Citation Analysis]
28 Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, Wang XH, Ray SC, Thomas DL. Cross-genotype immunity to hepatitis C virus. J Virol 2004;78:1575-81. [PMID: 14722311 DOI: 10.1128/jvi.78.3.1575-1581.2004] [Cited by in Crossref: 139] [Cited by in F6Publishing: 73] [Article Influence: 7.7] [Reference Citation Analysis]
29 Knox JJ, Kaplan DE, Betts MR. T-bet-expressing B cells during HIV and HCV infections. Cell Immunol 2017;321:26-34. [PMID: 28739077 DOI: 10.1016/j.cellimm.2017.04.012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
30 Lanford RE, Walker CM, Lemon SM. The Chimpanzee Model of Viral Hepatitis: Advances in Understanding the Immune Response and Treatment of Viral Hepatitis. ILAR J 2017;58:172-89. [PMID: 29045731 DOI: 10.1093/ilar/ilx028] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
31 Fuller MJ, Shoukry NH, Gushima T, Bowen DG, Callendret B, Campbell KJ, Hasselschwert DL, Hughes AL, Walker CM. Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology 2010;51:378-87. [PMID: 19918975 DOI: 10.1002/hep.23319] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 4.6] [Reference Citation Analysis]
32 Abdel-Hakeem MS, Shoukry NH. Protective immunity against hepatitis C: many shades of gray. Front Immunol. 2014;5:274. [PMID: 24982656 DOI: 10.3389/fimmu.2014.00274] [Cited by in Crossref: 51] [Cited by in F6Publishing: 60] [Article Influence: 6.4] [Reference Citation Analysis]
33 Barth H, Rybczynska J, Patient R, Choi Y, Sapp RK, Baumert TF, Krawczynski K, Liang TJ. Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. Hepatology. 2011;54:1135-1148. [PMID: 21674561 DOI: 10.1002/hep.24489] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
34 Freeman ZT, Cox AL. Lessons from Nature: Understanding Immunity to HCV to Guide Vaccine Design. PLoS Pathog 2016;12:e1005632. [PMID: 27362419 DOI: 10.1371/journal.ppat.1005632] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
35 Shteyer E, Shekhtman L, Zinger T, Harari S, Gafanovich I, Wolf D, Ivgi H, Barsuk R, Dery I, Armoni D, Rivkin M, Pipalia R, Cohen Eliav M, Skorochod Y, Breuer GS, Tur-Kaspa R, Weil Wiener Y, Stern A, Cotler SJ, Dahari H, Lurie Y. Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography. PLoS One 2019;14:e0210173. [PMID: 30645600 DOI: 10.1371/journal.pone.0210173] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
36 Verstrepen BE, Boonstra A, Koopman G. Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees. World J Hepatol 2015; 7(1): 53-69 [PMID: 25624997 DOI: 10.4254/wjh.v7.i1.53] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
37 Manickam C, Martinot AJ, Jones RA, Varner V, Reeves RK. Hepatic immunopathology during occult hepacivirus re-infection. Virology 2017;512:48-55. [PMID: 28915405 DOI: 10.1016/j.virol.2017.08.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
38 Galal IF, Zakaria Z, Allam WR, Mahmoud MA, Ezzat AR, Osman A, Waked I, Strickland GT, Abdelwahab SF. Cross reactive cellular immune response to HCV genotype 1 and 4 antigens among genotype 4 exposed subjects. PLoS One 2014;9:e101264. [PMID: 24979366 DOI: 10.1371/journal.pone.0101264] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
39 Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer G, Page K, Lloyd AR, Dore GJ. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis. 2012;12:408-414. [PMID: 22541630 DOI: 10.1016/s1473-3099(12)70010-5] [Cited by in Crossref: 144] [Cited by in F6Publishing: 73] [Article Influence: 14.4] [Reference Citation Analysis]
40 Berzofsky JA, Ahlers JD, Janik J, Morris J, Oh S, Terabe M, Belyakov IM. Progress on new vaccine strategies against chronic viral infections. J Clin Invest 2004;114:450-62. [PMID: 15314679 DOI: 10.1172/JCI22674] [Cited by in Crossref: 4] [Cited by in F6Publishing: 39] [Article Influence: 0.2] [Reference Citation Analysis]
41 Vickerman P, Grebely J, Dore GJ, Sacks-Davis R, Page K, Thomas DL, Osburn WO, Cox AL, Aitken CK, Hickman M, Hellard M; International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3). The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. J Infect Dis 2012;205:1342-50. [PMID: 22457292 DOI: 10.1093/infdis/jis213] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 5.4] [Reference Citation Analysis]
42 Ortega-prieto AM, Dorner M. Novel methods to prevent HCV transmission. Future Virology 2017;12:471-3. [DOI: 10.2217/fvl-2017-0072] [Reference Citation Analysis]
43 Zubkova I, Duan H, Wells F, Mostowski H, Chang E, Pirollo K, Krawczynski K, Lanford R, Major M. Hepatitis C virus clearance correlates with HLA-DR expression on proliferating CD8+ T cells in immune-primed chimpanzees. Hepatology. 2014;59:803-813. [PMID: 24123114 DOI: 10.1002/hep.26747] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
44 Bigger CB, Guerra B, Brasky KM, Hubbard G, Beard MR, Luxon BA, Lemon SM, Lanford RE. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 2004;78:13779-92. [PMID: 15564486 DOI: 10.1128/JVI.78.24.13779-13792.2004] [Cited by in Crossref: 204] [Cited by in F6Publishing: 119] [Article Influence: 11.3] [Reference Citation Analysis]
45 Neumann-Haefelin C, Spangenberg HC, Blum HE, Thimme R. Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection. World J Gastroenterol 2007; 13(36): 4839-4847 [PMID: 17828815 DOI: 10.3748/wjg.v13.i36.4839] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
46 Park SH, Veerapu NS, Shin EC, Biancotto A, McCoy JP, Capone S, Folgori A, Rehermann B. Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Nat Med 2013;19:1638-42. [PMID: 24270546 DOI: 10.1038/nm.3408] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
47 Dahari H, Feinstone SM, Major ME. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology. 2010;139:965-974. [PMID: 20621699 DOI: 10.1053/j.gastro.2010.05.077] [Cited by in Crossref: 74] [Cited by in F6Publishing: 74] [Article Influence: 6.2] [Reference Citation Analysis]
48 Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, Walker CM. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med. 2003;197:1645-1655. [PMID: 12810686 DOI: 10.1084/jem.20030239] [Cited by in Crossref: 467] [Cited by in F6Publishing: 434] [Article Influence: 24.6] [Reference Citation Analysis]
49 Dustin LB, Cashman SB, Laidlaw SM. Immune control and failure in HCV infection--tipping the balance. J Leukoc Biol. 2014;96:535-548. [PMID: 25015956 DOI: 10.1189/jlb.4ri0214-126r] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
50 Major M, Gutfraind A, Shekhtman L, Cui Q, Kachko A, Cotler SJ, Hajarizadeh B, Sacks-Davis R, Page K, Boodram B, Dahari H. Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users. Sci Transl Med 2018;10:eaao4496. [PMID: 29997251 DOI: 10.1126/scitranslmed.aao4496] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 8.3] [Reference Citation Analysis]
51 Hartlage AS, Murthy S, Kumar A, Trivedi S, Dravid P, Sharma H, Walker CM, Kapoor A. Vaccination to prevent T cell subversion can protect against persistent hepacivirus infection. Nat Commun 2019;10:1113. [PMID: 30846697 DOI: 10.1038/s41467-019-09105-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
52 Walker CM. Adaptive immunity to the hepatitis C virus. Adv Virus Res 2010;78:43-86. [PMID: 21040831 DOI: 10.1016/B978-0-12-385032-4.00002-1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
53 Stoll-Keller F, Barth H, Fafi-Kremer S, Zeisel MB, Baumert TF. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines. 2009;8:333-345. [PMID: 19249975 DOI: 10.1586/14760584.8.3.333] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 4.8] [Reference Citation Analysis]
54 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2004; 12(7): 1650-1655 [DOI: 10.11569/wcjd.v12.i7.1650] [Reference Citation Analysis]
55 Bailey JR, Barnes E, Cox AL. Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. Gastroenterology. 2019;156:418-430. [PMID: 30268785 DOI: 10.1053/j.gastro.2018.08.060] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 18.3] [Reference Citation Analysis]
56 Shoukry NH. Hepatitis C Vaccines, Antibodies, and T Cells. Front Immunol 2018;9:1480. [PMID: 30002657 DOI: 10.3389/fimmu.2018.01480] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 10.3] [Reference Citation Analysis]
57 Bukh J, Thimme R, Meunier JC, Faulk K, Spangenberg HC, Chang KM, Satterfield W, Chisari FV, Purcell RH. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J Virol 2008;82:8183-95. [PMID: 18550671 DOI: 10.1128/JVI.00142-08] [Cited by in Crossref: 66] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
58 Zeisel MB, Fafi-Kremer S, Fofana I, Barth H, Stoll-Keller F, Doffoël M, Baumert TF. Neutralizing antibodies in hepatitis C virus infection. World J Gastroenterol 2007; 13(36): 4824-4830 [PMID: 17828813 DOI: 10.3748/wjg.v13.i36.4824] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
59 McMullan LK, Grakoui A, Evans MJ, Mihalik K, Puig M, Branch AD, Feinstone SM, Rice CM. Evidence for a functional RNA element in the hepatitis C virus core gene. Proc Natl Acad Sci USA. 2007;104:2879-2884. [PMID: 17299041 DOI: 10.1073/pnas.0611267104] [Cited by in Crossref: 96] [Cited by in F6Publishing: 92] [Article Influence: 6.4] [Reference Citation Analysis]
60 Walker CM, Grakoui A. Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection? Curr Opin Immunol 2015;35:137-43. [PMID: 26241306 DOI: 10.1016/j.coi.2015.06.010] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 6.6] [Reference Citation Analysis]